Sunshine Biopharma Enters At-The-Market Sales Agreement With Aegis Capital For Up To $4 Million - SEC Filing
SBFM•ATM sales agreement with Aegis Capital
July 20 (Reuters) - Sunshine Biopharma Inc. SBFM.O:
- Sunshine Biopharma enters at-the-market sales agreement with Aegis Capital for up to $4 million - SEC filing
Source text: [ID:n0001683168-26-005656]
Further company coverage: SBFM.O
